361 related articles for article (PubMed ID: 15816500)
41. [Advantages of active vitamin D metabolites in the treatment of osteoporosis as compared with calciferol].
Zofková I
Vnitr Lek; 2001 Feb; 47(2):99-100. PubMed ID: 15635854
[TBL] [Abstract][Full Text] [Related]
42. Vitamin D therapy for chronic kidney disease.
Bhan I; Thadhani R
Semin Nephrol; 2009 Jan; 29(1):85-93. PubMed ID: 19121478
[TBL] [Abstract][Full Text] [Related]
43. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
Covic A; Voroneanu L; Goldsmith D
Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478
[TBL] [Abstract][Full Text] [Related]
44. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
Brown AJ; Slatopolsky E
Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
[TBL] [Abstract][Full Text] [Related]
45. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
46. Role of vitamin d receptor activators in cardio-renal syndromes.
Cozzolino M; Bruschetta E; Stucchi A; Ronco C; Cusi D
Semin Nephrol; 2012 Jan; 32(1):63-9. PubMed ID: 22365164
[TBL] [Abstract][Full Text] [Related]
47. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
[TBL] [Abstract][Full Text] [Related]
48. Vitamin D and cardiovascular disease.
Nemerovski CW; Dorsch MP; Simpson RU; Bone HG; Aaronson KD; Bleske BE
Pharmacotherapy; 2009 Jun; 29(6):691-708. PubMed ID: 19476421
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
50. [Cardioprotective effect of vitamin D in nondialyzed patients with stage 3-5 CKD].
Cozzolino M; Mehmeti F; Bonelli F; Ronga C; Musetti C; Missaglia E; Stucchi A; Colombo F; Tavecchia M; Cuoccio P; Brenna I; Volpi E; Ciceri P; Cusi D
G Ital Nefrol; 2010; 27 Suppl 52():S27-31. PubMed ID: 21132659
[TBL] [Abstract][Full Text] [Related]
51. Vitamin D receptor ligand therapy in chronic kidney disease.
Gonzalez E
Clin Nephrol; 2008 Oct; 70(4):271-83. PubMed ID: 18826852
[TBL] [Abstract][Full Text] [Related]
52. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.
Andress DL
Kidney Int; 2006 Jan; 69(1):33-43. PubMed ID: 16374421
[TBL] [Abstract][Full Text] [Related]
53. Impact of kidney bone disease and its management on survival of patients on dialysis.
Lee GH; Benner D; Regidor DL; Kalantar-Zadeh K
J Ren Nutr; 2007 Jan; 17(1):38-44. PubMed ID: 17198930
[TBL] [Abstract][Full Text] [Related]
54. Vitamin D: the iceberg nutrient.
Armas LA; Heaney RP
J Ren Nutr; 2011 Mar; 21(2):134-9. PubMed ID: 21239184
[TBL] [Abstract][Full Text] [Related]
55. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
[TBL] [Abstract][Full Text] [Related]
56. Bone disease in uremic patients: advances in PTH suppression.
Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
[TBL] [Abstract][Full Text] [Related]
57. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Effect of vitamin D on kidney and cardiovascular system].
Fujii H
Clin Calcium; 2010 Jul; 20(7):1045-50. PubMed ID: 20585183
[TBL] [Abstract][Full Text] [Related]
58. Combination vitamin D therapy in stage 5 chronic kidney disease.
Vondracek SF; Hoody DW
Ann Pharmacother; 2011 Jul; 45(7-8):1011-5. PubMed ID: 21750312
[TBL] [Abstract][Full Text] [Related]
59. [Vitamin D: synthesis, metabolism, regulation, and an assessment of its deficiency in patients with chronic renal disease].
Spustová V; Dzúrik R
Vnitr Lek; 2004 Jul; 50(7):537-43. PubMed ID: 15323262
[TBL] [Abstract][Full Text] [Related]
60. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
Drüeke TB; McCarron DA
N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
